相互作用
Efgartigimod / hyaluronidase sc + Nivolumab
重症度: 中等度
Efgartigimod / hyaluronidase sc and Nivolumab: moderate interaction.
最終更新日
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
概要
Subcutaneous efgartigimod blocks the neonatal Fc receptor, which normally protects IgG antibodies from degradation. Nivolumab is an IgG4 antibody, so its clearance could increase and exposure fall, potentially weakening antitumor effect. The clinical significance is uncertain.
この相互作用をわかりやすく説明すると
Efgartigimod / hyaluronidase sc and Nivolumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
なぜ起こるのか
Efgartigimod blocks FcRn-mediated IgG recycling, which may accelerate catabolism of IgG-based nivolumab.
対処法
Avoid combining where possible, or monitor tumor response closely if efgartigimod is necessary. Involve oncology and neurology specialists in weighing alternatives.
薬剤師に尋ねること
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Efgartigimod / hyaluronidase scとNivolumabの臨床対応の詳細なアドバイス、追加の注記、エビデンスの詳細、処方全体を対象とした相互作用チェッカーを利用できます。
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
WebでPro+を7日間無料でお試し。カード登録不要。
Nivolumabのその他の相互作用
よくある質問
Can I take Efgartigimod / hyaluronidase sc with Nivolumab?
MediHelp rates the interaction as moderate. Efgartigimod / hyaluronidase sc and Nivolumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Subcutaneous efgartigimod blocks the neonatal Fc receptor, which normally protects IgG antibodies from degradation. Nivolumab is an IgG4 antibody, so its clearance could increase and exposure fall, potentially weakening antitumor effect. The clinical significance is uncertain.
How serious is the interaction between Efgartigimod / hyaluronidase sc and Nivolumab?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid combining where possible, or monitor tumor response closely if efgartigimod is necessary. Involve oncology and neurology specialists in weighing alternatives.
What other medicines interact with Nivolumab?
MediHelp also lists interactions of Nivolumab with, for example, Thalidomide, Dexamethasone-tobramycin, Dexamethasone. The full list is on the Nivolumab page.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
